Q1 2024 Financial Highlights: Wantai Bio's Net Profit Plummets by 90%, AstraZeneca Reports 19% Revenue Growth
WANTAI BioPharm
Biological Diagnostic Reagents and Vaccine R&D, Manufacturer
AstraZeneca
Pharmaceutical Technology Research and Development Provider
ASYMCHEM
Pharmaceutical R&D and Production Outsourcing Service Provider
Sanofi
Pharmaceutical Manufacturer
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
Qyuns
Developer of Biologics for Autoimmune and Allergic Diseases
EasyDiagnosis
Developer, Manufacturer, and Seller of In Vitro Diagnostic Reagents and Supporting Instruments
Xingqi Pharmaceutical
Ophthalmic Drug Research, Development, Production, and Sales
Sinocelltech
Innovative Biopharmaceutical R&D Developer
Sanyou Medical
Developer, Manufacturer, and Supplier of Medical Orthopedic Implants
The 2-valent HPV vaccine continues to face fierce competition.
On April 25, WANTAI BioPharm released its Q1 2024 financial report. During the reporting period, the company achieved revenue of 753 million yuan, a year-on-year decrease of 73.93%; net profit was 126 million yuan, a year-on-year decrease of 89.9%.
CXO Giants Are Also Having a Hard Time.
Today, ASYMCHEM disclosed its Q1 2024 report. During the reporting period, the company achieved operating revenue of 1.399 billion yuan, a year-on-year decrease of 37.76%; net profit attributable to parent company was 280 million yuan, a year-on-year decrease of 55.27%.
Foreign companies have also successively announced their first-quarter reports.
Today, AstraZeneca's Q1 2024 financial report shows that the company's total revenue during the reporting period was $12.679 billion, a year-on-year increase of 19%, including product revenue of $12.177 billion, a year-on-year increase of 18%. Notably, the global total sales of DS8201 in Q1 were $879 million, an increase of $348 million compared to the same period last year.
Sanofi Announces Q1 2024 Financial Report: Revenue Reached €10.464 Billion, a Year-on-Year Increase of 6.7%
In the past day, what are the hot topics in the pharmaceutical markets at home and abroad that are worth paying attention to? Let Aji lead you to take a look.
/ 01 /
Market Express
1) Hansoh Pharma Introduces QX004N Antibody from Quanxin Bio
On April 25, Hansoh Pharma announced that it had entered into a licensing agreement with Quanxin Biotech to obtain the rights to develop and commercialize the QX004N monoclonal antibody in China (including Hong Kong, Macao, and Taiwan).
/ 02 /
Capital Information
1) EasyDiagnosis Plans to Use Up to 40 Billion Yuan of Idle Self-Owned Funds for Entrusted Wealth Management
On April 25, EasyDiagnosis announced that the company and its subsidiaries plan to use no more than 40 billion yuan of idle self-owned funds to purchase low-risk wealth management products.
2) Tasly's Q1 net profit increased by 11.58% year-on-year
On April 25, Tasly disclosed its Q1 2024 report. During the reporting period, the company achieved operating revenue of 2.049 billion yuan, a year-on-year decrease of 1.73%; net profit attributable to parent company was 295 million yuan, a year-on-year increase of 11.58%.
3) Xingqi Pharmaceutical's Q1 net profit increased by 79.59% year-on-year
On April 25, Xingqi Pharmaceutical disclosed its Q1 2024 financial report. During the reporting period, the company achieved operating revenue of 349 million yuan, a year-on-year increase of 22.10%; net profit was 34.75 million yuan, a year-on-year increase of 79.59%.
4) Sinocelltech Turns Profitable Year-on-Year in Q1
On April 25, Sinocelltech Group Limited announced its Q1 2024 financial report. During the reporting period, the company achieved operating revenue of 613 million yuan, representing a year-on-year increase of 86.30%; net profit attributable to shareholders of the listed company was 74.1974 million yuan, turning losses into profits year-on-year.
5) Sanyou Medical Plans to Purchase Equity of Shuimu Tianpeng and Investment Shares of Shanghai Huanzhan
On April 25, Sanyou Medical announced that it is planning to acquire the equity of Waterwood Tianpeng and the capital contribution share of Shanghai Huanzhan by issuing shares and paying cash, while simultaneously raising supporting funds.
6) ASYMCHEM's Q1 net profit decreased by 55.27% year-on-year
On April 25, ASYMCHEM disclosed its Q1 2024 earnings report. During the reporting period, the company achieved operating revenue of 1.399 billion yuan, a year-on-year decrease of 37.76%; net profit attributable to parent company was 280 million yuan, a year-on-year decrease of 55.27%.
7) WANTAI BioPharm's Q1 Net Profit Decreased by 89.9% Year-on-Year
On April 25, WANTAI BioPharm released its Q1 2024 financial report. During the reporting period, the company achieved revenue of 753 million yuan, a year-on-year decrease of 73.93%; net profit was 126 million yuan, a year-on-year decrease of 89.9%.
8) MicroPort EP Turns Profit in Q1
On April 25, MicroPort EP disclosed its Q1 2024 financial report. During the reporting period, the company achieved a total operating revenue of 89.1525 million yuan, representing a year-on-year increase of 71.01%. The net profit was 4.1692 million yuan, turning losses into profits compared to a loss of 9.3261 million yuan in the same period last year.
9) Sanyou Medical's Q1 revenue reaches 267 million yuan
On April 25, Sanyou Medical announced its Q1 2024 financial report. During the reporting period, the company achieved operating revenue of 267 million yuan, a year-on-year increase of 28.72%, and a net profit attributable to shareholders of 91.1191 million yuan, a year-on-year increase of 171.88%.
10）Ailis Q1 Net Profit of 301 Million Yuan
On April 25, Alis released its Q1 2024 report. During the reporting period, the company achieved revenue of 742 million yuan, a year-on-year increase of 168%; non-GAAP net profit was 301 million yuan, a year-on-year increase of 1423.83%.
/ 03 /
Pharmaceuticals and Medical Devices Dynamics
1) China Biologic Products TQA3038 Completes Phase I Clinical Study
On April 25, China Biologic Products announced that TQA3038 (siRNA), a Class 1 innovative drug independently developed by its subsidiary Zhengda Tianqing Pharmaceutical, had successfully completed Phase I clinical research.
2) C-CAR031, a GPC3-targeted armored chimeric antigen receptor autologous T-cell injection developed by Sybiam Biotech, approved for clinical trials
On April 25, according to the CDE official website, CellBioMed's GPC3-targeted armored chimeric antigen receptor autologous T-cell injection C-CAR031 has been approved for clinical trials, intended for use in GPC3+ advanced/recurrent hepatocellular carcinoma.
3) Rongsheng Pharmaceutical's Human Coagulation Factor IX Approved for Clinical Use
On April 25, according to the CDE official website, Rongsheng Pharmaceutical's human coagulation factor IX has been approved for clinical use, intended for the treatment of bleeding in patients with coagulation factor IX deficiency (hemophilia B).
4) KSH01 Injection by Coshera Approved for Clinical Trials
On April 25, according to the CDE official website, KSH01 Injection from Keshihua was approved for clinical trials, aiming to conduct research on the treatment of advanced solid tumors.
5) Minghui Pharmaceutical's MH004 Ointment Approved for Clinical Trials
On April 25, according to the CDE official website, Minghui Pharmaceutical's MH004 Ointment has been approved for clinical trials, intended for the treatment of atopic dermatitis patients.
6) Hengbang Pharma's HS-10374 Tablets Approved for Clinical Trials
On April 25, according to the CDE official website, Hengbang Pharmaceutical's HS-10374 tablet has been approved for clinical trials and is intended for the treatment of alopecia areata.
7) Huajian Future HJ787 Ointment Approved for Clinical Trials
On April 25, according to the CDE official website, Huajian Future's HJ787 Ointment has been approved for clinical trials, intended for the treatment of psoriasis.
8) Abbisko's FGFR4 Inhibitor Granted FDA Orphan Drug Designation
On April 25, Abbisko Therapeutics announced that its self-developed highly selective small molecule FGFR4 inhibitor, Erapogatinib, has been granted Orphan Drug Designation by the U.S. FDA for the treatment of hepatocellular carcinoma.
/ 04 /
Overseas Pharmaceutical News
1) FDA Approves New Antibiotic for Non-Complicated Urinary Tract Infections
On April 24, the FDA approved the listing of Utility Therapeutics' oral antibiotic pivmecillinam for the treatment of non-complicated urinary tract infections caused by Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
2) AstraZeneca's First Quarter Revenue Increased by 19% Year-on-Year
On April 25, AstraZeneca announced its Q1 2024 financial report. During the reporting period, total revenue reached $12.679 billion, increasing by 19% year-over-year. Product revenue amounted to $12.177 billion, marking an 18% increase year-over-year. Notably, the global sales of DS8201 in Q1 totaled $879 million, reflecting an increase of $348 million compared to the same period last year.
3) Sanofi's First Quarter Revenue Increased by 6.7% Year-over-Year
On April 25, Sanofi announced its financial report for the first quarter of 2024. During the reporting period, the company's revenue was 10.464 billion euros, increasing by 6.7% year-on-year (at constant exchange rates).
Text / Huang Kai
PS: Welcome to scan the QR code below to add the WeChat ID of AminoGenius for communication.
